A February 2026 ADAP Watch report from the National Association of State and Territorial AIDS Directors (NASTAD) finds that multiple states are cutting or restricting programs that help people with HIV obtain antiretroviral drugs and insurance assistance. The report ties these moves to federal funding for the Ryan White HIV/AIDS Program and related supports that “have remained relatively unchanged over the last decade,” even as enrollment and drug prices have risen, leaving states to cover widening budget gaps.
Scope of changes
– At least 18 states have already put cost‑containment measures in place, and more than 20 have either adopted or are considering restrictions.
– Common actions include lowering income‑eligibility thresholds, narrowing drug formularies, limiting drug coverage, tightening enrollment and recertification procedures, and reducing or ending insurance premium assistance.
Notable state examples
– Florida reduced ADAP eligibility from 400% to 130% of the federal poverty level, a change NASTAD estimates will affect more than 12,000 clients. The state also stopped covering the single‑tablet regimen Biktarvy and restricted Descovy to patients with specific clinical needs.
– Pennsylvania cut eligibility from 500% to 350% of the federal poverty level, affecting roughly 1,600 clients.
– Kansas lowered premium‑assistance eligibility from 400% to 250% of the federal poverty level.
– Delaware and Rhode Island have reduced eligibility caps.
– Arizona, Michigan, and Nevada have tightened recertification rules or pared back formularies.
– Alaska and Oklahoma reinstated stricter six‑month recertification policies.
Why this matters
ADAPs (AIDS Drug Assistance Programs) supply antiretroviral therapy and help pay insurance premiums for low‑ and middle‑income people living with HIV. Continuous treatment suppresses viral replication, preserves immune function, and prevents transmission. Reducing eligibility, cutting covered drugs, or shrinking insurance support can interrupt treatment, allowing the virus to rebound, increasing the risk of illness and the development of drug resistance, and undermining population‑level progress toward viral suppression.
Funding context and reactions
NASTAD links state cost‑containment to stagnant federal appropriations amid rising need and drug costs. Broader reductions in federal support for research and prevention have intensified fiscal pressure on state programs. Advocacy organizations say sustained federal investment is essential to maintain access and to meet goals for ending the epidemic. The CEO of AIDS United emphasized that robust federal funding for prevention, treatment, and support services is critical and noted that each HIV infection prevented avoids an estimated half‑million dollars in lifetime treatment costs.
Implications
State cuts may leave many people without direct access to antiretrovirals or premium assistance, increasing strain on clinics and community providers and risking worse health outcomes and higher long‑term costs. Experts warn that shrinking public health infrastructure now could lead to greater expenses and harm later if treatment access deteriorates and transmission rises.
